The New Human Blood Type That Only 3 People on Earth Have—And the Hunt for the 4th

Why It Matters

Ultra‑rare blood types complicate transfusion compatibility and underscore the need for broader genetic screening in blood banks. Understanding such mutations can improve donor matching and inform future personalized medicine.

Key Takeaways

• B(A) blood type discovered in three people at Thai hospital.
• Mutation involves four genes, producing mostly B antigens with trace A.
• Raises total known human blood types to 49.
• Highlights limits of current ABO typing for transfusion safety.
• Suggests more undiscovered rare blood groups worldwide.

Pulse Analysis

The identification of a new blood phenotype, labeled B(A), underscores how much genetic variation remains hidden in the human population. Discovered during routine typing at a Bangkok hospital, the mutation was found in only three individuals—a patient and two donors—making it one of the rarest documented blood groups. By expanding the catalog from 48 to 49 types, the finding challenges the long‑standing perception that the ABO system captures all clinically relevant antigens. For transfusion services, even a single unrecognized antigen can trigger severe reactions, prompting a reevaluation of screening protocols for ultra‑rare donors.

The B(A) phenotype arises from a quartet of linked gene alterations that shift the balance of surface sugars, producing predominantly B antigens while retaining trace A epitopes. This hybrid expression confounds standard serological tests, which typically classify samples as either pure B or AB. Advanced genomic sequencing was required to pinpoint the four‑gene mutation and differentiate it from known alleles. Such complexity illustrates why reliance on phenotypic typing alone can miss critical incompatibilities, especially in multicultural populations where rare alleles may be more prevalent.

Beyond transfusion safety, the B(A) discovery fuels broader research into blood‑group genetics and personalized medicine. As genome‑wide studies expand, clinicians anticipate uncovering additional ultra‑rare phenotypes that could influence drug metabolism, disease susceptibility, and immune response. International blood banks are now considering collaborative registries to track such anomalies and facilitate matched donations across borders. However, ethical questions arise regarding privacy, consent, and the commercial value of rare genetic information. Balancing scientific insight with patient rights will be essential as the catalog of human blood types continues to grow.